• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconNovo Nordisk

Novo Nordisk

Page 3 of 9
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
By Lindsey LeakeJanuary 21, 2025
Chairman & Chief Executive Officer of LVMH, Bernard Arnault attends the Viva Technology show at Parc des Expositions Porte de Versailles on May 23, 2024 in Paris, France.
Success
LVMH dethrones Novo Nordisk as Europe’s most valuable company as Bernard Arnault adds $12 billion to net worth in 2025
By Ryan HoggJanuary 20, 2025
Danish Prime Minister Mette Frederiksen (R) and Greenlandic Prime Minister Mute Bourup Egede address a press conference in the Mirror Hall at the Prime Minister's Office, at Christiansborg in Copenhagen, on January 10, 2025.
Leadership
Novo Nordisk CEO attends crisis talks with Danish PM amid Donald Trump Greenland threats
By Ryan HoggJanuary 17, 2025
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
Health
Elon Musk admits he takes an Ozempic-like weight-loss drug that RFK Jr. wants to restrict
By Alexa MikhailDecember 27, 2024
Novo Nordisk advertising flags and logo on facade, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health
Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
By Ryan Hogg and AFPDecember 20, 2024
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
Tech
Novo Nordisk invests $1.2 billion in new Danish factory to expand beyond insulin and weight-loss
By AFPDecember 16, 2024
Close-up of a patient administering a dose of Zepbound (tirzepatide)
Health
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
By Lindsey LeakeDecember 4, 2024
Mads Krogsgaard Thomsen, chief executive officer of Novo Nordisk Foundation, during a panel session on day two of the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, May 24, 2022.
Health
Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ as ‘fundamentally different’ for Denmark’s economy
By Ryan HoggNovember 26, 2024
Novo Nordisk launches Wegovy in China with prices well below U.S.
Health
Novo Nordisk launches Wegovy in China with prices well below U.S.
By Amber Tong and BloombergNovember 18, 2024
Novo Nordisk’s Wegovy sales jump on international rollouts
Retail
Novo Nordisk’s Wegovy sales jump on international rollouts
By Naomi Kresge and BloombergNovember 6, 2024
Many hundred of spectators watch Queen Margrethe of Denmark while the Royal Guard takes her through the city of Kalundborg in a coach during her visit to the city where she commence a two days visit on June 13, 2017 in Kalundborg, Denmark.
Lifestyle
Danish manufacturing hub of weight-loss wonderdrug Ozempic is an epicenter for childhood overweightedness
By Ryan HoggNovember 4, 2024
A hand is seen holding Ozempic.
Health
Novo’s main Ozempic plant cited for quality lapses by FDA
By Madison Muller and BloombergOctober 29, 2024
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
Health
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By Lindsey LeakeOctober 10, 2024
Ozempic goes from threat to opportunity for packaged-food makers
Health
Ozempic goes from threat to opportunity for packaged-food makers
By Deena Shanker and BloombergOctober 2, 2024
A person holds up a box of Ozempic.
Health
Ozempic may help manage opioid addiction: study
By Naomi Kresge and BloombergSeptember 25, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...9
Most Popular
Success
Mark Cuban says he has the solution to growing income inequality, and it's to reward every employee—from CEO to janitor—with company stockplaceholder alt text
By Sasha RogelbergJuly 20, 2026
Success
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billionplaceholder alt text
By Sydney LakeJuly 20, 2026
AI
'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimisticplaceholder alt text
By Jason MaJuly 18, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.